$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
舒尼替尼与化疗联合治疗NSCLC患者安全耐受
2025-10-19 11:44:20
Check Details
易瑞沙可用于晚期化疗失败的肺癌患者
2025-10-19 11:44:20
Check Details
特罗凯治疗肺鳞癌效果优于化疗
2025-10-19 11:44:20
Check Details
色瑞替尼治疗ALK阳性NSCLC疗效优于化疗
2025-10-19 11:44:20
Check Details
肺癌患者服用舒尼替尼常见的不良反应
2025-10-19 11:44:20
Check Details
克唑替尼使ROS1阳性NSCLC获益
2025-10-19 11:44:20
Check Details
奥希替尼治疗EGFR突变阳性的NSCLC有效率高达80%
2025-10-19 11:44:20
Check Details
艾乐替尼治疗亚洲肺癌患者疗效显著
2025-10-19 11:44:20
Check Details
克唑替尼获批我国ALK阳性NSCLC患者的治疗
2025-10-19 11:44:20
Check Details
吉非替尼 vsxa0长春瑞滨治疗非小细胞肺癌老年患者:II期研究
2025-10-19 11:44:20
Check Details
阿法替尼治疗晚期鳞状细胞非小细胞肺癌
2025-10-19 11:44:20
Check Details
艾乐替尼治疗ALK阳性NSCLC的优势
2025-10-19 11:44:20
Check Details
1
2
...
9069
9070
9071
9072
9073
9074
9075
...
10234
10235
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma
2
Lemborexant for Insomnia: Dual Orexin 5/10mg, 7-Hour Bedtime, 7–10-Day Review and Safety
3
Fayuvi (rebisufligene etisparvovec-hopf) for MPS IIIA: AAV9 Single Infusion, Weight-Based Dose, Steroids, Liver/Platelet Monitoring
4
Trelagliptin Once-Weekly DPP-4 for Type 2 Diabetes: Dosing, Renal Adjustment, Discontinuation
5
Orforglipron (Foundayo) vs Metformin: Oral GLP-1 Weight Loss and T2D Use
6
Fayuvi (rebisufligene etisparvovec-hopf/UX111) for MPS IIIA: AAV9 SGSH Gene Therapy, Cognition, and Safety
7
Ramosetron Hydrochloride Orally Disintegrating Tablets: A 5-HT3 Receptor Antagonist for Diarrhea-Predominant IBS
8
Finerenone (Kerendia) for Diabetic CKD and HF with LVEF≥40%: Albuminuria, Dosing, Hyperkalemia
9
Baxdrostat (Baxfendy) for Hypertension: Aldosterone Synthase Inhibition, Dosing, and Discontinuation Rules
10
Pixclara (Floretyrosine F-18/18F-FET) Glioma PET: Distinguishing Recurrence from Treatment-Related Change
11
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
12
Bexlutry (Lu-177 Dotatate) for SSTR-Positive GEP-NETs: PRRT Dosing and Safety Monitoring